Analysts Set La Jolla Pharmaceutical (LJPC) Price Target at $51.83

La Jolla Pharmaceutical (NASDAQ:LJPC) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $51.83.

A number of equities analysts have recently commented on LJPC shares. SunTrust Banks set a $45.00 price objective on La Jolla Pharmaceutical and gave the stock a “buy” rating in a research note on Thursday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $53.00 price objective on shares of La Jolla Pharmaceutical in a research note on Thursday, August 9th. Chardan Capital reiterated a “buy” rating and issued a $115.00 price objective on shares of La Jolla Pharmaceutical in a research note on Monday, June 18th. ValuEngine upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, May 24th. Finally, BidaskClub upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 24th.

A number of hedge funds have recently added to or reduced their stakes in LJPC. SG Americas Securities LLC acquired a new stake in La Jolla Pharmaceutical during the first quarter worth about $134,000. Trexquant Investment LP acquired a new stake in La Jolla Pharmaceutical during the first quarter worth about $795,000. Prudential Financial Inc. grew its position in La Jolla Pharmaceutical by 8.7% during the first quarter. Prudential Financial Inc. now owns 203,089 shares of the biopharmaceutical company’s stock worth $6,048,000 after buying an additional 16,200 shares in the last quarter. Swiss National Bank grew its position in La Jolla Pharmaceutical by 12.6% during the first quarter. Swiss National Bank now owns 33,100 shares of the biopharmaceutical company’s stock worth $986,000 after buying an additional 3,700 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in La Jolla Pharmaceutical by 14.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 86,430 shares of the biopharmaceutical company’s stock worth $2,574,000 after buying an additional 11,132 shares in the last quarter.

La Jolla Pharmaceutical stock opened at $20.60 on Wednesday. La Jolla Pharmaceutical has a 52 week low of $20.25 and a 52 week high of $41.36.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($2.02) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.07). The firm had revenue of $1.59 million during the quarter, compared to analyst estimates of $2.48 million. sell-side analysts anticipate that La Jolla Pharmaceutical will post -7.69 EPS for the current year.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Recommended Story: What is a Stop Order?

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply